Survival according to early ctDNA dynamics in advanced breast cancer (ABC) treated with endocrine therapy (ET) and a CDK4/6 inhibitor (CDK4/6i)

被引：0

作者：

Martinez Saez, O. ^{[1
]}

Felip Falgas, E. ^{[2
]}

Cappelletti, M. ^{[3
]}

Tolosa, P. ^{[4
]}

Braso-Maristany, F. ^{[5
]}

Sanfeliu Torres, E. ^{[6
]}

Pascual, T. ^{[1
]}

Chic, N. ^{[1
]}

Vidal, M. ^{[1
]}

Adamo, B. ^{[1
]}

Munoz, M. ^{[1
]}

Faull, I. ^{[7
,8
]}

Odegaard, J. ^{[9
]}

Patel, G. ^{[10
]}

McEwen, R. ^{[11
]}

Carroll, D. ^{[11
]}

Ciruelos, E. M. ^{[4
]}

Generali, D. G. ^{[12
]}

Margeli Vila, M. ^{[13
]}

Prat, A. ^{[1
]}

机构：

[1] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[2] Hosp Badalona Germans Trias & Pujol, ICO Inst Catala Oncol Badalona, Med Oncol Dept, Barcelona, Spain

[3] ASST Cremona Azienda Socio Sanitaria Terr, Dept Med Oncol, Cremona, Italy

[4] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain

[5] IDIBAPS Inst Invest Biomed August Pi i Sunyer, Oncol Dept, Barcelona, Spain

[6] Hosp Clin Barcelona, Pathol, Barcelona, Spain

[7] Guardant Hlth, Med Dept, Barcelona, Spain

[8] Guardant Hlth, Business Dev, Barcelona, Spain

[9] Guardant Hlth, Clin Dev, Redwood City, CA USA

[10] AstraZeneca, Clin Dev Dept, Macclesfield, Cheshire, England

[11] AstraZeneca, Oncol R&D, Oncol, Cambridge, England

[12] ASST Cremona Azienda Sociosanit Terr, Dept Med Oncol, Cremona, CR, Italy

[13] Hosp Badalona Germans Trias & Pujol, ICO Inst Catala Oncol Badalona, Med Oncol Dept, Badalona, Spain

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.03.025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

10P

引用

页码：S127 / S128

页数：2

共 50 条

[21] Breast cancer: CDK4/6 inhibitor plus fulvestrant prolongs survival
Lorenz, Judith
GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (02)
[22] Pfizer's CDK4/6 inhibitor approved for advanced breast cancer
Chris Morrison
Nature Biotechnology, 2015, 33 : 323 - 324
[23] Targeting CDK4/6 in breast cancer
Shanabag, Anusha
Armand, Jessica
Son, Eugene
Yang, Hee Won
EXPERIMENTAL AND MOLECULAR MEDICINE, 2025, 57 (02): : 312 - 322
[24] CDK4/6 inhibitors in breast cancer
Dukelow, Tim
Kishan, Divya
Khasraw, Mustafa
Murphy, Conleth G.
ANTI-CANCER DRUGS, 2015, 26 (08) : 797 - 806
[25] Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (vol 12, 5112, 2021)
Alves, Carla L.
Ehmsen, Sidse
Terp, Mikkel G.
Portman, Neil
Tuttolomondo, Martina
Gammelgaard, Odd L.
Hundebol, Monique F.
Kaminska, Kamila
Johansen, Lene E.
Bak, Martin
Honeth, Gabriella
Bosch, Ana
Lim, Elgene
Ditzel, Henrik J.
NATURE COMMUNICATIONS, 2021, 12 (01)
[26] Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
Herrera-Abreu, M. T.
Guan, J.
Khalid, U.
Ning, J.
Costa, M. R.
Chan, J.
Li, Q.
Fortin, J-p.
Wong, W. R.
Perampalam, P.
Biton, A.
Sandoval, W.
Vijay, J.
Hafner, M.
Cutts, R.
Wilson, G.
Frankum, J.
Roumeliotis, T. I.
Alexander, J.
Hickman, O.
Brough, R.
Haider, S.
Choudhary, J.
Lord, C. J.
Swain, A.
Metcalfe, C.
Turner, N. C.
NATURE COMMUNICATIONS, 2024, 15 (01)
[27] Will women with breast cancer (BC) be willing to take an adjuvant CDK4/6 inhibitor in addition to endocrine therapy (ET)?
Jesin, Jessica
Desautels, Danielle
Kiss, Alex
Warner, Ellen
Jerzak, Katarzyna Joanna
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[28] Improving Breast Cancer Therapy With CDK4/6 Inhibitors
Jaganathan, Hamsa
Overstreet, Karen
Reed, Elizabeth
CLINICAL BREAST CANCER, 2014, 14 (06) : 379 - 380
[29] The role of CDK4/6 inhibitors in early breast cancer
Gil-Gil, Miguel
Alba, Emilio
Gavila, Joaquin
de la Haba-Rodriguez, Juan
Ciruelos, Eva
Tolosa, Pablo
Candini, Daniele
Llombart-Cussac, Antonio
BREAST, 2021, 58 : 160 - 169
[30] Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
Martin, Miguel
Garcia-Saenz, Jose A.
Manso, Luis
Llombart, Antonio
Cassinello, Alejo
Atienza, Manuel
Ringeisen, Francois
Ciruelos, Eva
FUTURE ONCOLOGY, 2020, 16 (33) : 2763 - 2778

← 1 2 3 4 5 →